Genetic Function – Page 5

Arrowhead Pharmaceuticals Shifts Focus to Plozasiran, Deprioritizes Zodasiran in Cardiometabolic Drug Development

10 months ago talkbio0Tagged Arrowhead, cardiometabolic drug, Cardiovascular Diseases, LDL Cholesterol Lipoproteins, Plozasiran, RNA Interference, Triglycerides, zodasiran

Arrowhead Pharmaceuticals, cardiometabolic drug, plozasiran, zodasiran, RNAi therapies, cardiovascular disease, triglycerides, LDL cholesterol

Alnylam Achieves Breakthrough in Heart Study with RNAi Therapy Vutrisiran

10 months ago talkbio0Tagged Alnylam, Amyloidosis, Cardiomyopathies, RNA Interference, TTR wt Allele, vutrisiran

Alnylam, Vutrisiran, RNAi Therapy, Heart Study, ATTR Amyloidosis, Cardiomyopathy

RYBREVANT: A Breakthrough in Lung Cancer Treatment

11 months ago talkbio0Tagged Epidermal Growth Factor Receptor, Infusion-Related Reaction, intravenous administration, Malignant neoplasm of lung, Mutation, Non-Small Cell Lung Carcinoma, Rybrevant, subcutaneous administration, Survival Rate

RYBREVANT, lung cancer, EGFR mutations, subcutaneous administration, intravenous administration, infusion-related reactions, survival rate, non-small cell lung cancer (NSCLC)

ExpressionEdits Secures $13M in Seed Funding to Revolutionize Protein Therapies with AI-Driven Intronization Technology

11 months ago talkbio0Tagged Biotechnology, ExpressionEdits, intronization, Plant seeds, protein expression, protein therapies, Technology

ExpressionEdits, Protein therapies, AI-driven intronization technology, Seed funding, Biotechnology, Protein expression

Pioneering Gene Therapy Restores Hearing in Children with Otoferlin-Linked Deafness

12 months ago talkbio0Tagged Child, Clinical Trials, gene therapy, Hearing, hearing restoration, Mutation

Gene therapy, otoferlin-related deafness, hearing restoration, children, genetic mutation, clinical trial, auditory function.

Harmony Pharmaceuticals Expands into Rare Genetic Epilepsies with Acquisition of Epygenix Therapeutics

12 months ago talkbio0Tagged Acquisition (action), CDK-like kinase inhibitors, Collaboration, development aspects, Epygenix, genetic epilepsies, Harmony Pharmaceuticals, Infantile Severe Myoclonic Epilepsy, Mutation, research

Harmony Pharmaceuticals, Epygenix Therapeutics, rare genetic epilepsies, acquisition, treatment, research, development, collaboration, genetic mutations, Dravet syndrome, CDK-like kinase inhibitors

Moderna Collaborates with OpenAI for Seamless Integration of GenAI in Operations

12 months ago talkbio0Tagged Artificial Intelligence, Biotechnology, DNA Integration, GenAI, Moderna, OpenAI, Partnership, Seamless, Surgical aspects

Moderna, OpenAI, GenAI, seamless integration, operations, biotechnology, artificial intelligence, partnership

Roche and Alnylam’s Hypertension Hopeful Zilebesiran Shows Promising Results in Combination Therapy Trial

1 year ago talkbio0Tagged Alnylam, Angiotensinogen, Combined Modality Therapy, control of blood pressure, Hypertensive disease, Intravascular systolic:Pressure:Point in time:Arterial system:Quantitative, RNA Interference, Roche (company), Safety, Zilebesiran

Roche, Alnylam, Zilebesiran, Hypertension, Combination Therapy, Phase 2 Trial, Blood Pressure Control, AngioTensinogen (AGT), RNA Interference (RNAi) Therapeutic, Significant Reductions in Systolic Blood Pressure, Encouraging Safety Profile

Second Positive Phase 2 Trial Boosts Confidence in Alnylam’s RNAi Blood Pressure Med, Supporting Roche’s $2.8 Billion Biobucks Bet

1 year ago talkbio0Tagged Alnylam, blood pressure medication, Hypertension therapy, KARDIA-2, milestone payments, Partnership, RNA Interference, Roche (company), Systolic blood pressure reduction, Zilebesiran

Alnylam RNAi blood pressure medication, Zilebesiran, Phase 2 trial success, Systolic blood pressure reduction, Roche partnership, $2.8 billion milestone payments, Hypertension therapy, KARDIA-2 study

J&J Scores First-Line Approval for Rybrevant Combination in Lung Cancer with EGFR Exon 20 Mutations

1 year ago talkbio0Tagged amivantamab-vmjw, Approved, carboplatin-pemetrexed chemotherapy, Disease Progression, EGFR Exon 20, first-line, Insertion Mutation, Johnson and Johnson, Mortality Risk, Non-Small Cell Lung Carcinoma, Objective Response Rate, ORR, Progression-Free Survival, Reduced, Rybrevant, United States Food and Drug Administration

Johnson & Johnson, Rybrevant (amivantamab-vmjw), FDA Approval, First-Line Treatment, Non-Small Cell Lung Cancer (NSCLC), EGFR Exon 20 Insertion Mutations, Carboplatin-Pemetrexed Chemotherapy, Phase 3 PAPILLON Study, Reduced Disease Progression or Mortality Risk, Improved Objective Response Rate (ORR) and Progression-Free Survival (PFS)